The Latest Cardiac and Vascular News
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 New patent issued by USPTO for use of Gencaro in treating atrial fibrillation in heart failure patients with ejection fractions greater than 40% WESTMINSTER, Colo., March 18, 2021 […]
SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection fraction will be presented in a Late Breaking Clinical Trial […]
New Board Appointment Brings Demonstrated Leadership in the Medical Device Industry CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB) today announced the appointment of John Sheridan to the Company’s Board of Directors effective March 17, 2021. Since March 2019, Mr. Sheridan has been the President and […]
CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended December 31, 2020. Recent Highlights: Reported revenue of $2.6 million […]
BRADENTON, Fla.–(BUSINESS WIRE)–PaceMate™, the leading digital healthcare company in compliant cardiac data management, announced today its recent listing with premier electronic health record company Epic. As part of the App Orchard developer program, PaceMate™’s bidirectional, EHR-integrated application is now available to Epic’s vast network of healthcare customers as a comprehensive, […]
MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $3.50 per […]
Latest System Designed for Single Session Arterial Thrombus Removal ALAMEDA, Calif.–(BUSINESS WIRE)–Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. commercial availability of the Indigo® System Lightning™ 7. Lightning 7 expands Penumbra’s offering of the Indigo Aspiration System with Intelligent Aspiration for mechanical thrombectomy and is […]
Novel XO Cross catheter platform CE Mark cleared for use in peripheral vasculature. PARK CITY, Utah, March 17, 2021 /PRNewswire/ — Transit Scientific announced it received CE Mark approval in the European Union for its non-tapered metal alloy XO CrossÒ Microcatheter platform. Microcatheters are commonly used to provide guidewire support, facilitate guidewire exchanges, access distal […]
MONMOUTH JUNCTION, N.J., March 16, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO) announces the filing of an Investigational Device Exemption (IDE) application to conduct the clinical study, “Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T),” in the United States to support an initial FDA regulatory approval. This is being done under the previously announced FDA Breakthrough Designation granted for the removal of […]
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke […]
